Saul Dr Tzipori

7910706, Mar 22, 2011

Sep 14, 2007

11/855699

Saul Tzipori - Shrewsbury MA, US
Ramaswamy Balakrishnan - Chadds Ford PA, US
Arthur Donohue-Rolfe - Maynard MA, US

Trustees of Tufts College - Medford MA

C07K 16/00
C12P 21/08

53038815, 5303884

Novel human monoclonal antibodies derived from a transgenic mouse are disclosed as well as a process for the preparation of the novel monoclonals and a therapeutic method of treating an individual for hemolytic uremic syndrome or of protecting an individual against hemolytic uremic syndrome by administration of the monoclonals to the individual in need of treatment or protection.

8614083, Dec 24, 2013

Jun 13, 2008

12/602819

Saul Tzipori - Shrewsbury MA, US
Udi Zukerman - Brookline MA, US
Gary Stacey - Marshfield MA, US

Trustees of Tufts College - Medford MA
Haemonetics - Braintree MA

C12N 3/00

435242, 4352521, 435261

A method for the simultaneous concentration of multiple toxins from large volumes of water. The method includes the steps of providing a disposable separation centrifuge bowl, the centrifuge bowl including a positively charged material at it's inner core. A large water sample contaminated with toxins from a group consisting of protozoa, bacteria, bacterial spores, and toxins is delivered to the centrifuge bowl. A centrifugal force is applied to the separation bowl. The water sample is concentrated to remove large particles of the toxins in the bowl due to the centrifugal forces. The concentrated water sample is passes through the positively charged inner core to capture any remaining concentrated targets by electrostatic forces and the concentrated targets are eluted.

8206940, Jun 26, 2012

May 15, 2009

12/992330

Hanping Feng - Framingham MA, US
Saul Tzipori - Shrewsbury MA, US
Guilin Yang - Shenzhen, CN

Tufts University - Boston MA

G01N 33/53

435 732, 435 72, 435 71, 435 29, 435 34, 435 39, 4242471, 4241671

Cell-based methods for rapid real time assay of a presence of toxin and/or cells are provided, using an assay having a toxin-enhancing antibody and a sensitive cell line carrying FcyR receptors, and kits for this assay. An ultrasensitive cell based immunocytotoxicity assay for detecting less then 1 pg/ml of toxins in clinical samples. A TcdA-specific monoclonal antibody, AIH3, was found to significantly enhance the cytotoxicity of TcdA to macrophages and monocytes. The AIH3-dependent enhancement of glucosyltransferase activity, cytoskeleton disruption, and TNF-a production induced by TcdA was demonstrated also in RAW 264. 7 cells. Methods for high level recombinant expression of toxins in cells, and vectors for expression, strains of carrying the vectors are provided.

20020160005, Oct 31, 2002

Jan 7, 2002

10/041958

Saul Tzipori - Shrewsbury MA, US
Ramaswamy Balakrishnan - Chadds Ford PA, US
Arthur Donohue-Rolfe - Maynard MA, US

TRUSTEES OF TUFTS COLLEGE

A61K039/40
C12N005/06
C12P021/04

424/150100, 435/070210, 435/340000

Novel human monoclonal antibodies derived from a transgenic mouse are disclosed as well as a process for the preparation of the novel monoclonals and a therapeutic method of treating an individual for hemolytic uremic syndrome or of protecting an individual against hemolytic uremic syndrome by administration of the monoclonals to the individual in need of treatment or protection.

20030082189, May 1, 2003

Aug 29, 2002

10/230614

Saul Tzipori - Shrewsbury MA, US
Ramaswamy Balakrishnan - Framingham MA, US
Arthur Donohue-Rolfe - Sudbury MA, US

Trustees of Tufts College

A61K039/40

424/164100

Disclosed is a therapeutic method for the treatment of hemolytic uremic syndrome. More specifically, the method includes the administration of monoclonal antibodies, chimeric monoclonal antibodies and monospecific polyclonal antibodies specific for Shiga like toxin.

20080038262, Feb 14, 2008

Aug 24, 2007

11/844945

Saul Tzipori - Shrewsbury MA, US
Ramaswamy Balakrishnan - Chadds Ford PA, US
Arthur Donohue-Rolfe - Maynard MA, US

A61K 39/395
A61P 43/00

424133100, 424150100

Novel human monoclonal antibodies derived from a transgenic mouse are disclosed as well as a process for the preparation of the novel monoclonals and a therapeutic method of treating an individual for hemolytic uremic syndrome or of protecting an individual against hemolytic uremic syndrome by administration of the monoclonals to the individual in need of treatment or protection.

20090068176, Mar 12, 2009

Oct 31, 2007

11/933166

Saul Tzipori - Shrewsbury MA, US
Ramaswamy Balakrishnan - Chadds Ford PA, US
Arthur Donohue-Rolfe - Maynard MA, US

A61K 39/395
A61P 13/00

4241331, 4241421

Human and humanized monoclonal antibodies which binds specifically to subunit A of Shiga like toxin II have been developed which are effective to prevent or ameliorate one or more symptoms of HUS in a human. Effective dosages for treatment or prevention range from approximately 0.1 to 5.0 mg of antibody/kg of patient weight. The examples demonstrate the preferred dosage ranges based on the pig model, and what is being tested in phase I clinical trials. Antibodies are preferably transfused over a period of two hours, although this will depend on the patient and the disease state at the time of treatment. Preferred dosages for treatment of humans are between 0.1 mg/kg-5.0 mg/kg of 5C120, or an equivalent dosage of another antibody to subunit A of STX2. In the most preferred embodiments, dosages of 0.1 mg/kg, 0.5 mg/kg, or 5.0 mg/kg of 5C12 (low dose, anticipated therapeutic dose based on animal data and high dose) are administered.

20090136916, May 28, 2009

Aug 13, 2008

12/191132

David W. Brown - North Brookfield MA, US
John E. Herrmann - Northboro MA, US
Saul Tzipori - Shrewsbury MA, US
Kerry B. Gunning - Coralville IA, US

TRUSTEES OF TUFTS COLLEGE - Medford MA

C12Q 1/70
C40B 60/10
C07H 21/02
C07H 21/04
C40B 50/14

435 5, 506 38, 536 2372, 536 2432, 506 30

The present invention relates to methods, microarrays and kits for detecting one or more human astrovirus serotypes in a sample (e.g., a fecal sample) from an individual. The method includes amplifying nucleic acid molecules of the sample with one or more primers, to thereby obtain an amplified nucleic acid product; contacting the amplified nucleic acid product with one or more serotype specific probes having a nucleic acid sequence that is specific for only one astrovirus serotype in the group of astroviruses being assessed, wherein the nucleic acid sequence includes between about 9 and 25 nucleic acid bases (e.g., SEQ ID NO: 5-24); and detecting the hybridization complex. The presence of hybridization complexes with a serotype specific probe indicates the presence of one or more specific astrovirus serotypes, and the absence of hybridization complexes with a serotype specific probe indicates the absence of the specific astrovirus serotype. Identification of the astrovirus serotypes allows for one to diagnose an individual infected with the serotype. The present invention further includes microarrays having any one of the astrovirus specific probe, or kits having microarrays and reagents for carrying out the assay.